Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Steroids. 2010 Feb 21;75(11):766–771. doi: 10.1016/j.steroids.2010.02.010

Figure 1.

Figure 1

Treatment of a mouse model of SLE with rosiglitazone reduces renal inflammation. (A) Previous work from our laboratory show that macrophage and monocyte infiltration (noted by black arrows) is reduced in the kidneys of the NZBWF1 mouse model of SLE after treatment with rosiglitazone (image taken at 40× magnification) (B) The expression of the chemokine, osteopontin, is reduced in the renal cortex of NZBWF1 mice treated with rosiglitazone. (figures from reference 21)